The Bill & Melinda Gates Foundation has been one of the largest private funders of vaccination programs in India for over two decades, and that involvement has generated both documented public-health achievements and real controversies that continue to shape debate. The story is not a simple tale of philanthropy gone right or a conspiracy of harm. It includes a parliamentary investigation into ethical violations during HPV vaccine trials, a contested statistical link between oral polio vaccine campaigns and a rise in non-polio paralysis cases, the co-development of one of the world’s cheapest rotavirus vaccines, and the construction of digital cold-chain systems that reshaped how India delivers immunizations. Understanding what actually happened requires separating the documented record from the misinformation that has grown around it.
The HPV Vaccine Trial Controversy
The single most cited episode in the “Gates and India vaccines” narrative involves a project run between 2009 and 2010 by PATH, an international health nonprofit that received substantial funding from the Gates Foundation. PATH administered the human papillomavirus (HPV) vaccine to roughly 20,000 girls aged 10 to 14 in the Indian states of Andhra Pradesh and Gujarat. The project was framed by PATH as a “demonstration project” to study how HPV vaccination could be delivered in low-resource settings. It used two commercially licensed vaccines, Gardasil and Cervarix, that had already been approved by regulators in multiple countries.
The project drew intense scrutiny after several girls who had been vaccinated died in the months following immunization. India’s Parliamentary Standing Committee on Health and Family Welfare launched an investigation, and its 72nd Report was scathing. The committee concluded that the project was functionally a clinical trial, regardless of how PATH labeled it, and that by operating under the guise of a demonstration project, PATH had violated Indian laws governing clinical trials.1Indian Journal of Medical Ethics. Trials and tribulations: an expose of the HPV vaccine trials by the 72nd Parliamentary Standing Committee Report The panel overseeing India’s health ministry agreed, stating the project had breached medical ethics and violated Indian clinical trial regulations.2BMJ. Indian MPs criticise HPV vaccination project for ethical violations
The ethical violations identified were specific and procedural. Consent forms were described as “incomplete and inaccurate.” In Andhra Pradesh, hostel wardens were directed to sign consent forms on behalf of parents and guardians, rather than the parents themselves providing informed consent. No insurance cover was arranged for the girls participating. The parliamentary report also criticized the project’s design for resulting in gross under-reporting of adverse events and questioned the reported figures for non-serious adverse events.1Indian Journal of Medical Ethics. Trials and tribulations: an expose of the HPV vaccine trials by the 72nd Parliamentary Standing Committee Report Subsequent medical investigations attributed the deaths to causes unrelated to the vaccine itself, but the consent and oversight failures were real and serious, and they became a lasting source of distrust toward foreign-funded vaccine programs in India.
It is worth being precise about what was established and what was not. The parliamentary investigation found that PATH broke India’s rules on informed consent, trial registration, and adverse-event monitoring. It did not find that the HPV vaccines themselves were unsafe. The distinction matters because the episode is frequently cited online as evidence that the Gates Foundation tested dangerous vaccines on Indian children. The documented problem was not a dangerous vaccine; it was a dangerous disregard for the rights of the people receiving it.
The Polio Campaign and Non-Polio Acute Flaccid Paralysis
India’s polio eradication campaign, which the Gates Foundation helped fund extensively starting in the late 1990s, is widely considered one of the great public-health success stories of the 21st century. India recorded its last case of wild poliovirus in January 2011 and was officially declared polio-free in 2014. Getting there required an enormous logistical effort: hundreds of millions of doses of oral polio vaccine (OPV) delivered through repeated “pulse polio” immunization rounds across the country.
A separate and more contentious question involves what happened to rates of non-polio acute flaccid paralysis (NPAFP) during the same period. Acute flaccid paralysis is a sudden onset of weakness in the limbs, and surveillance systems track it as an indicator of possible polio circulation. The expected background rate of NPAFP in a population is roughly 1 to 2 cases per 100,000. By the early 2010s, India’s nationwide NPAFP rate had climbed to about 12 per 100,000, far above what would be expected.3Pediatrics. Trends in Nonpolio Acute Flaccid Paralysis Incidence in India 2000 to 2013
Researchers examined whether the increase in NPAFP correlated with the intensity of OPV campaigns. A study looking at state-level data found a statistically significant correlation between NPAFP rates and the number of pulse polio rounds conducted in a given year. The correlation was strongest in the high-intensity states of Uttar Pradesh and Bihar, and when researchers looked at the cumulative effect of OPV doses administered over five years, the association grew stronger. When India reduced the number of pulse polio rounds starting around 2012, NPAFP rates began to decline, a pattern consistent with the hypothesis that OPV contributed to the rise.4PubMed Central. Correlation between Non-Polio Acute Flaccid Paralysis Rates with Pulse Polio Frequency in India
This finding has been used in anti-vaccine circles to claim that the Gates-funded polio campaign “paralyzed” hundreds of thousands of Indian children. The reality is more complicated. OPV uses a live, weakened poliovirus, and it has long been known that in rare cases the vaccine virus can revert to a form capable of causing paralysis, a phenomenon called vaccine-derived poliovirus. The global health community has acknowledged this trade-off for decades, which is one reason wealthier nations switched to the injectable, inactivated polio vaccine (IPV) years ago. The correlation observed in the Indian data is consistent with what virologists would expect from very high-dose OPV campaigns, but it does not mean that every NPAFP case was caused by the vaccine. NPAFP has many possible causes, and surveillance systems in India were simultaneously becoming more sensitive during this period, which could contribute to higher detection rates. The honest assessment is that the aggressive OPV campaign likely contributed to a portion of the NPAFP increase, but the magnitude of that contribution and how much was due to improved surveillance remain debated.
The Shift Toward Inactivated Polio Vaccine
The known risks of OPV have driven a global push to transition toward inactivated polio vaccine, which cannot cause vaccine-derived paralysis because it uses killed virus. India has been part of this transition, and recent research has explored whether lower-cost formulations of IPV could make the switch feasible at scale. A phase 3 trial in Indian infants compared a reduced-dose adjuvanted IPV with a standard full-dose IPV and found that the reduced-dose version produced comparable immune responses across all three poliovirus types, with seroconversion rates above 94% in both groups and no causally related serious adverse events.5The Lancet Infectious Diseases. Safety and immunogenicity of a reduced-dose adjuvanted inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in India If dose-sparing IPV formulations prove effective at scale, they could make the transition away from OPV more affordable for countries like India, addressing the very concern that the NPAFP data raised.
The Pentavalent Vaccine Debate
Another thread in the broader narrative involves the introduction of the pentavalent vaccine, a combination vaccine that protects against diphtheria, pertussis, tetanus, hepatitis B, and Haemophilus influenzae type b (Hib). India began introducing a liquid pentavalent vaccine (LPV) in certain states, and its rollout was followed by reports of infant deaths among recipients. Media coverage and some advocacy groups compiled these reports and argued that the vaccine was causing more deaths than the Hib disease it was meant to prevent.6PubMed. Pentavalent vaccine and adverse events following immunization-untangling the misinterpretations
Evaluating those claims requires understanding a basic epidemiological reality: in a country where millions of infants are vaccinated in a given year, some of those infants will die from causes unrelated to vaccination simply because infant mortality from other causes is not zero. The critical question is whether the death rate among vaccinated infants exceeds the background death rate. Indian and international regulatory bodies reviewed the reported deaths and concluded that the observed rate did not exceed what would be expected by chance. Critics countered that adverse-event reporting was inadequate and that the reviews were not independent enough. The Gates Foundation’s funding of GAVI, which helped finance the pentavalent vaccine’s introduction in India, placed it at the center of these disputes. The scientific consensus holds that the pentavalent vaccine’s safety profile is comparable to its predecessor vaccines, but the controversy contributed to a broader pattern of suspicion toward externally funded immunization programs.
Rotavac and the Model of Affordable Vaccine Development
Not everything about the Gates Foundation’s involvement in Indian vaccination fits neatly into the controversy frame. One of the more interesting chapters is the development of Rotavac, India’s homegrown rotavirus vaccine. Rotavirus is the leading cause of severe diarrheal disease in young children worldwide, and before Rotavac, the available rotavirus vaccines were priced well beyond what India’s public health system could afford.
Rotavac was developed through a partnership that included Indian researchers, the Indian government, PATH, and the Gates Foundation, with the manufacturing done by Bharat Biotech, an Indian company. The financial arrangement was distinctive: Bharat Biotech received major funding to conduct the expensive phase 3 clinical trial and some development costs, and in return committed to providing the vaccine to India and to GAVI-eligible countries at roughly one dollar per dose.7The Journal of Infectious Diseases. The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease At the time, competing rotavirus vaccines cost several times more per dose. India introduced Rotavac into its national immunization program, and the vaccine has since been prequalified by the WHO for global use.
The Rotavac story illustrates an aspect of the Gates Foundation’s work in India that gets less attention than the controversies: using philanthropic funding to de-risk vaccine development so that Indian manufacturers can produce affordable vaccines for both domestic and global use. Whether you view that as genuine partnership or as a form of pharmaceutical influence depends partly on where you sit, but the concrete outcome was a vaccine that India both produces and uses at a price its public health system can sustain.
India’s Position as a Global Vaccine Supplier
India’s vaccine manufacturing sector is enormous and predates the Gates Foundation’s involvement by decades. Indian manufacturers belonging to the Developing Countries Vaccine Manufacturers Network supply roughly 70% of the vaccines used in the global Expanded Program on Immunization.8PubMed. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices Companies like the Serum Institute of India, Bharat Biotech, and Biological E are among the largest vaccine producers in the world by volume. This capacity means that when the Gates Foundation or GAVI funds vaccine programs in India, they are often working with Indian manufacturers, not importing products from Western pharmaceutical companies.
This matters for the narrative because one common framing presents the Gates Foundation as imposing Western vaccines on India. The reality is more tangled. Indian companies manufacture many of the vaccines in question, Indian scientists lead much of the research, and India’s regulatory bodies approve the products. The Gates Foundation’s funding often flows through or alongside Indian institutions. That does not immunize the arrangement from criticism, but it does complicate the picture of a foreign billionaire unilaterally experimenting on an unwilling population.
Patent Barriers and the Cost of New Vaccines
One area where the interests of global health organizations and Indian manufacturers have not always aligned is intellectual property. A study examining patent landscapes for HPV, rotavirus, and pneumococcal vaccines found intense patenting activity that could delay the entry of new manufacturers in countries including India.9Vaccine. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines When patents held by multinational companies restrict Indian manufacturers from producing generic versions of newer vaccines, it limits the competitive pressure that keeps vaccine prices low. The Gates Foundation has sometimes funded technology transfer to work around these barriers, as with Rotavac, but the structural tension between patent protection and affordable access persists across most newer vaccine platforms.
India’s own pharmaceutical industry has historically thrived on producing affordable generic drugs and vaccines, and the country’s patent laws have provisions, like compulsory licensing, that allow production of patented products under certain conditions. But newer, more complex vaccines are harder to reverse-engineer than small-molecule drugs, and the patent thickets around them are denser. The result is a landscape where India can produce billions of doses of older vaccines cheaply but faces real barriers to manufacturing the newest ones without partnerships or licensing deals, many of which involve organizations like GAVI and the Gates Foundation.
Digital Infrastructure for Vaccine Delivery
Beyond the vaccines themselves, the Gates Foundation and allied organizations have invested in the logistics of getting vaccines from factories to children’s arms. One example is the electronic vaccine intelligence network (eVIN), introduced by India’s Ministry of Health and Family Welfare starting in 2014 and implemented by the United Nations Development Programme with support from GAVI. The system replaced paper-based cold-chain management with an electronic logistics platform across 12 states during its initial phase.10PubMed Central. Return on investment of the electronic vaccine intelligence network in India
Cold-chain management matters because many vaccines lose potency if they are not kept within a specific temperature range from the point of manufacture to the point of administration. In a country as large and geographically varied as India, with health facilities ranging from well-equipped urban hospitals to remote rural clinics, maintaining the cold chain is a persistent challenge. Electronic monitoring systems like eVIN can flag temperature excursions in real time and help planners allocate vaccine stocks more efficiently, reducing both waste and stockouts. India has since expanded the system and developed its own digital health platforms, including CoWIN, which was built for COVID-19 vaccination tracking but drew on infrastructure and institutional knowledge that predated the pandemic.
How India’s Clinical Trial Regulations Changed
The controversies of the late 2000s and early 2010s had a tangible effect on India’s regulatory environment. In the decade following the HPV trial controversy, India overhauled its rules governing clinical trials. The regulatory landscape changed substantially, with new requirements around informed consent, compensation for trial-related injuries, and oversight of both domestic and foreign-funded studies.11PubMed Central. Regulatory requirements for clinical trials in India: What academicians need to know India’s drug regulatory authority, the Central Drugs Standard Control Organisation, tightened rules for ethics committees, mandated audio-visual documentation of the informed consent process in certain trial types, and introduced stricter timelines for reporting serious adverse events.
These reforms were driven partly by the parliamentary investigation into the HPV trial and partly by broader concerns about India being used as a site for clinical trials that primarily benefited populations in wealthier countries. The changes slowed the pace of new trial approvals for several years, which some researchers and pharmaceutical companies criticized as overcorrection. But they also addressed genuine gaps in the protections available to Indian trial participants. If the HPV controversy demonstrated what could go wrong when a foreign-funded health project operated with insufficient local oversight, the regulatory reforms that followed represent India’s institutional response to that failure.
GAVI and the Question of Equity
The Gates Foundation is the single largest private funder of GAVI, the global vaccine alliance that helps lower-income countries access new vaccines. India has been both a recipient and a manufacturer partner within the GAVI system. A review of GAVI’s policies over its first 15 years found that the alliance focused primarily on between-country equity, working to close the gap in vaccine access between lower-income GAVI-eligible countries and wealthier nations.12PubMed Central. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization
Within-country equity is a different challenge. India’s immunization coverage varies enormously by state, by urban versus rural setting, and by socioeconomic status. A child in Kerala is far more likely to be fully immunized than a child in a remote district of Uttar Pradesh. GAVI’s model of subsidizing vaccine purchases can help ensure that vaccines reach a country’s national program, but it does not automatically solve the last-mile delivery problems that leave the most marginalized children unvaccinated. Critics of the Gates Foundation’s approach to global health have argued that the emphasis on specific vaccine introductions can crowd out investment in the broader primary health care infrastructure that India needs to reach underserved populations. Supporters counter that vaccines are among the most cost-effective health interventions available and that waiting for perfect health systems before introducing life-saving vaccines costs lives.
Separating Documented Concerns from Conspiracy Narratives
Online discussions about “Bill Gates and India vaccines” often blend legitimate grievances with unfounded claims. The legitimate grievances include the consent violations in the HPV trial, the questions about NPAFP and aggressive OPV campaigns, and the broader concern about whether philanthropic organizations exercise too much influence over sovereign health policy. These are real issues that Indian researchers, parliamentarians, and civil society groups have raised through formal channels, and they deserve serious engagement rather than dismissal.
The unfounded claims tend to involve allegations that Gates used Indian children as guinea pigs for untested vaccines, that the polio campaign was deliberately designed to cause harm, or that vaccination programs are vehicles for population control or microchip implantation. These claims do not hold up against the evidence. The vaccines used in the Indian programs were, in almost every case, licensed products already in use in multiple countries. The polio campaign’s goal of eradicating a crippling disease was shared by the Indian government, the WHO, and Rotary International. The consent violations that occurred were failures of process, not evidence of sinister intent.
Drawing the line between these two categories is not always comfortable, because doing so requires acknowledging that a powerful foreign philanthropy did real things wrong in India while also rejecting the conspiratorial framing that inflates those wrongs into something they were not. The HPV trial violations were serious enough to prompt a parliamentary investigation and regulatory reform. They were not serious enough to support claims of deliberate medical experimentation. The NPAFP correlation with OPV rounds is a legitimate area of epidemiological inquiry. It is not evidence that Bill Gates personally paralyzed Indian children. Holding both of those truths at once is the intellectually honest position, even if it does not make for a tidy narrative on social media.